# Simulations Plus

> Simulations Plus develops scientific modeling software and provides consulting to pharmaceutical, biotechnology, regulatory and academic users worldwide. GastroPlus, ADMET Predictor, MonolixSuite and DILIsym address drug properties, absorption, population variability and safety; its wider portfolio includes QSP, training and clinical operations services. Altaris announced a proposed approximately $375 million acquisition in June 2026; the latest verified regulatory update, in August, described it as pending.

- **Founded:** 1996
- **Headquarters:** Research Triangle Park, United States
- **Founders:** Walter S. Woltosz (Cofounder; former CEO; board director), Virginia E. Woltosz (Cofounder; former Senior Vice President and Secretary)
- **Products:** GastroPlus, ADMET Predictor, MonolixSuite, DILIsym, Thales and QSP library models
- **Notable:** Founded in 1996 and marked its 25th anniversary in 2021., Company reported software/services involvement in development of a majority of FDA-approved drugs in 2024., DILIsym product page reports use in regulatory submissions for 38 compounds.

## Products & services

- **GastroPlus** — Mechanistic PBPK/PBBM simulation of absorption, exposure, formulation effects and drug interactions; first GastroPlus programming dates to 1997.
- **ADMET Predictor** — AI/ML molecular-property prediction, compound prioritization and customizable models; version 13 released in 2025.
- **MonolixSuite** — PKanalix, Monolix and Simulx connect PK analysis, population PK/PD modeling and clinical trial simulation.
- **DILIsym** — Mechanistic quantitative systems toxicology modeling for drug-induced liver injury; version 11 released in 2025.
- **Thales and QSP library models** — Quantitative systems pharmacology tools and disease models for mechanistic efficacy and treatment questions.
- **Pro-ficiency** — Simulation-based learning, clinical operations support and medical communications; acquired in 2024.
- **Composer** — AI workflow orchestration around scientific engines, with audit trails; public product page offers a waitlist.
- **Scientific consulting and training** — Discovery, PBPK, population PK/PD, QSP/QST, regulatory strategy, reporting, workshops and coaching.

## Achievements

- Founded in 1996 and marked its 25th anniversary in 2021.
- Company reported software/services involvement in development of a majority of FDA-approved drugs in 2024.
- DILIsym product page reports use in regulatory submissions for 38 compounds.

## Latest updates

- **2026-08** — HSR waiting period expired; acquisition still subject to other closing conditions in the August 13 announcement.
- **2026-07** — Third-quarter fiscal 2026 revenue rose 7% to $21.9 million; services grew 20% and software was flat.
- **2026-06** — Announced use of NVIDIA BioNeMo Agent Toolkit to build Composer’s agentic layer.
- **2026-06** — Altaris acquisition agreement announced; anticipated combination with Chemical Computing Group at or around closing.

## Links

- Website: https://www.simulations-plus.com/
- LinkedIn: https://www.linkedin.com/company/simulations-plus/
- Twitter/X: https://twitter.com/SimulationsPlus
- YouTube: https://www.youtube.com/c/SimulationsPlusInc
- Facebook: https://www.facebook.com/SimulationsPlus

---

Profile page: https://yespress.io/simulations-plus
Published by YesPress — https://yespress.io
Last updated: 2026-10-02